<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344992</url>
  </required_header>
  <id_info>
    <org_study_id>BC3-CT011</org_study_id>
    <secondary_id>2014-005028-92</secondary_id>
    <nct_id>NCT02344992</nct_id>
  </id_info>
  <brief_title>Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal</brief_title>
  <official_title>Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of BioChaperone to already marketed prandial insulin analogue accelerates the
      onset and shorten the duration of action of insulin lispro due to facilitation of the
      absorption of the insulin after subcutaneous injection.

      This trial is intented to compare the post-prandial blood glucose control of BioChaperone
      insulin lispro and Humalog® when injected after a standardized meal as well as the
      pharmacokinetic profile of BioChaperone insulin lispro and Humalog® in subjects with type 1
      diabetes mellitus.

      This is a double-blinded, randomized, controlled, two-period crossover phase Ib trial to
      compare the blood glucose control after ingestion of a standardized meal, with BioChaperone
      Lispro at 0.2U/Kg and Humalog at 0.2U/Kg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the blood glucose time curve: AUCbg(0-2h)</measure>
    <time_frame>2 hours</time_frame>
    <description>Area under the blood glucose concentration time curve from 0-2 hours after a standardised meal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: Area under the blood glucose concentration time curve from 0-8 hours after a standardized meal: AUCbg(0-8h)</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic: maximum blood glucose concentration after a standardized meal: BGmax</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: Area under the serum insulin lispro concentration time curve from 0-8hours: AUClisp(0-8h)</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: Maximum observed serum insulin lispro concentration: Cmax(lisp)</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters</measure>
    <time_frame>Up to 7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <arm_group>
    <arm_group_label>Biochaperone Insulin Lispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BioChaperone insulin lispro</intervention_name>
    <description>Single dose of 0.2 U/kg body weight injected subcutaneously</description>
    <arm_group_label>Biochaperone Insulin Lispro</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog®</intervention_name>
    <description>Single dose of 0.2 U/kg body weight injected subcutaneously</description>
    <arm_group_label>Humalog®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 Diabetes Mellitus ≥ 12 months

          -  Treated with multiple daily insulin injections or CSII ≥ 12 months

          -  BMI 18.5-28.0 kg/m² (both inclusive)

          -  HbA1C%≤9%

        Exclusion Criteria:

          -  Type 2 Diabetes Mellitus

          -  Receipt of any trial product within 60 days prior to this trial

          -  Clinically significant abnormal haematology, biochemistry, lipids or urinalysis
             screening tests as judged by the investigator considering the underlying disease

          -  Presence of clinically significant acute gastroinstestinal symptoms as judged by the
             investigator

          -  Known slowing of gastric emptying and or gastrointestinal surgery that in the opinion
             of the investigator might change gastrointestinal motility and food absorption.

          -  Any systemic treatment with drugs known to interfere with glucose metabolism

          -  Use of any tobacco or nicotine-contained product within one year prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grit Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

